Yes, let’s hope so. Seem the closer we get the more

New Post Public Reply Private Reply Replies (2) Message Board
trding Evil Rabbit #339
355
Yes, let’s hope so. Seem the closer we get the more vultures show up to try manipulation the share price.

If you have read some of the ghost of Tom Goad’s post on that sa article yesterday. He does a really good job.

https://seekingalpha.com/article/4243443-cytodyn-good-true

Here is one

Quote:
Completely fair take. I think it takes a deep dive into the history of CCR5 inhibitors and some understanding of the company's timelines to figure out why a deal hasn't occurred yet, but it now makes sense to me. It took me several years to reach the understanding and comfort level that I currently have with the company's financial situation, so I'm happy to share my perspective when I can. I actually posted on this at length on another article recently, so I'll copy and paste here for your convenience.
It's something of a long story, but in short... CCR5 inhibitors were all the rage for HIV a few years back, except they didn't tend to turn out that great. Maraviroc ($MRK) is approved, but has relatively low response rates and still struggles with toxicity. Vicriviroc ($PFE) never even got approved. There was promising cancer data generated in 2012 by a joint study from those two firms (led by Richard Pestell, now CMO at $CYDY), but that never advanced very far. There is currently a study going on with Keytruda and maraviroc, but CytoDyn IP would prevent it from being commercialized.
Study: www.fiercebiotech.com/...
IP: patents.justia.com/...
So leronlimab (nee Pro 140) was bought off the scrap heap a while back, and nobody gave it much of a chance to get anywhere. The FDA wanted a trial run for combination therapy for HIV before the company could advance it for monotherapy, presumably because the combo market is basically salvage (multi-drug resistance) patients that constitute an unmet medical need. That took time and money, and early mono trials showed middling results. However, thanks to the safety profile (no serious adverse effects noted to date in any trial over hundreds of patients and years of use), they realized that they could up the dosage, which turned in better and better HIV results. Most recently, their phase III combination therapy trial met primary endpoints, and an investigational phase IIb/III monotherapy trial showed 90%+ response rates as dosages increased.
Combo endpoints: www.cytodyn.com/...
Mono efficacy: www.cytodyn.com/...
But the potential introduction as a combination therapy was never a threat to any BP's cash cow, and until recently with the dosage escalations, monotherapy was hitting middling response rates as well. Therefore, nobody jumped at an acquisition or partnership.
In the meantime, Dr. Pestell (of the 2012 joint Merck/Pfizer study) learned about leronlimab and it's efficacy/safety profile as a CCR5 inhibitor. He approached the company about studying the compound independently as far back as maybe 2016 - the exact timeline on that is a bit unclear. His results impressed him, and CytoDyn bought Pestell's company - and IP - in 2018.
Acquisition: www.cytodyn.com/...
The cancer indication is important because once the company knew that a cancer indication was a real possibility, they weren't going to sell the company or license off the drug for peanuts. By the time the results from monotherapy trials showed it's potential as a disruptor in the HIV market, cancer was already on the table. No company is going to pay cancer money if the only thing proven is HIV, and CytoDyn won't accept HIV money for a drug with cancer platform potential. You're at a stalemate. So they've been selling shares to raise money for years, on terms that encouraged investors (economically, not explicitly) to sell the shares and keep the warrants. That, plus it's residence on the OTC, has kept the share price depressed through clinical successes, etc.
All of that said, they have enough cash and remaining authorized shares not yet issued to fund the current BLA for combination therapy and advance their first cancer trial, in triple negative breast cancer. If interim cancer data comes back positive, BP will likely be forced to move on some sort of a partnership. That hypothetically eliminates the need for further funding rounds, which breaks the current capital cycle, and should bring CytoDyn closer to a market valuation.
All of this ignores that the drug may also basically cure GvHD, and that Pestell's company brought over a prostate diagnostic test that is an improvement over current options and could hit the market in late 2019 or early 2020.
GvHD: www.cytodyn.com/...
Diagnostic test: www.cytodyn.com/...
I'd recommend watching a recent presentation by the principals of the company, CEO Dr. Nadar Pourhassan and CMO Dr. Richard Pestell, to better understand the progress the company has made.
Presentation: noble.mediasite.com/...

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 13

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 243

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 139

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 11

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 464

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 39

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 82

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 43

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading

Top 5 Most Recently Viewed Articles

Topicus.com Reports Q3 2025 Financial Results with Growth

Updated Category News Views 757

Financial Overview of Topicus.com Inc. for Q3 2025 In a significant financial announcement, Topicus.com Inc. (TSXV: TOI), in conjunction with Constellation Software Inc. (TSX: CSU), has shared their results for the third quarter of 2025. For the quarter ending on September 30, 2025, the total revenue reached €387.9 million, which reveals an impressive 24% increase from...

Continue Reading
First Financial Security, Inc. Executes a Strategic 10-for-1 Stock Split

Updated Category News Views 266

Strategic 10-for-1 Stock Split Announcement by First Financial Security, Inc. First Financial Security, Inc. (FFS) has recently announced a significant corporate action — a 10-for-1 stock split of its authorized shares of common stock. This adjustment is a clear indication of the company’s positive growth outlook and its unwavering commitment to providing enhanced...

Continue Reading
Octopus AIM VCT plc Reports Strong Net Asset Value Update

Updated Category News Views 55

Overview of Octopus AIM VCT plc Octopus AIM VCT plc is a distinguished investment firm known for its focus on investments in AIM-listed companies. The firm aims to provide investors with significant returns through its carefully managed portfolio, making it a key player in the investment landscape. With a commitment to transparency and value, Octopus AIM VCT plc regularly...

Continue Reading
Revolt CBD Shows Innovation and Growth in Its Latest Update

Updated Category News Views 180

Revolt CBD Launches Innovative Website Redesign In a significant move towards enhancing customer engagement, Revolt CBD has officially unveiled its newly redesigned website. This development marks a pivotal moment for the brand as it strives to improve accessibility, transparency, and innovation in 2026. The new online platform is designed to better reflect the brand's...

Continue Reading
Strategic Merger to Enhance Biopharmaceutical Innovations

Updated Category News Views 86

Exciting Merger Between ACELYRIN and Alumis The proposed merger between ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. marks a pivotal moment in the biopharma landscape focused on immune-mediated diseases. This partnership is set to create a robust clinical stage company, combining strengths and resources to deliver transformative treatment options to patients. Key...

Continue Reading